JP2023541671A5 - - Google Patents

Info

Publication number
JP2023541671A5
JP2023541671A5 JP2023517699A JP2023517699A JP2023541671A5 JP 2023541671 A5 JP2023541671 A5 JP 2023541671A5 JP 2023517699 A JP2023517699 A JP 2023517699A JP 2023517699 A JP2023517699 A JP 2023517699A JP 2023541671 A5 JP2023541671 A5 JP 2023541671A5
Authority
JP
Japan
Prior art keywords
composition according
seq
immunotherapy composition
item
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517699A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541671A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/045055 external-priority patent/WO2022060487A1/en
Publication of JP2023541671A publication Critical patent/JP2023541671A/ja
Publication of JP2023541671A5 publication Critical patent/JP2023541671A5/ja
Pending legal-status Critical Current

Links

JP2023517699A 2020-09-17 2021-08-06 シヌクレイノパチーの処置のためのアルファ-シヌクレインワクチン Pending JP2023541671A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079819P 2020-09-17 2020-09-17
US63/079,819 2020-09-17
PCT/US2021/045055 WO2022060487A1 (en) 2020-09-17 2021-08-06 Alpha-synuclein vaccine for the treatment of synucleinopathies

Publications (2)

Publication Number Publication Date
JP2023541671A JP2023541671A (ja) 2023-10-03
JP2023541671A5 true JP2023541671A5 (cg-RX-API-DMAC7.html) 2024-08-14

Family

ID=80777122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517699A Pending JP2023541671A (ja) 2020-09-17 2021-08-06 シヌクレイノパチーの処置のためのアルファ-シヌクレインワクチン

Country Status (12)

Country Link
US (1) US20230355756A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213867A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023541671A (cg-RX-API-DMAC7.html)
KR (1) KR20230087487A (cg-RX-API-DMAC7.html)
CN (1) CN116783211A (cg-RX-API-DMAC7.html)
AR (1) AR123189A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021344230A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192429A1 (cg-RX-API-DMAC7.html)
IL (1) IL301224A (cg-RX-API-DMAC7.html)
MX (1) MX2023003007A (cg-RX-API-DMAC7.html)
TW (1) TW202227465A (cg-RX-API-DMAC7.html)
WO (1) WO2022060487A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ-グルカン若しくはマンナンからなるか、又はこれを含む結合体
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物
JP2026521182A (ja) 2023-06-15 2026-06-26 スリーエム イノベイティブ プロパティズ カンパニー プライマー組成物、接着剤システム、及び関連プロセス

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2657953A1 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
LT3067066T (lt) * 2007-02-23 2019-06-25 Prothena Biosciences Limited Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas
PL2583978T3 (pl) * 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CA2697373C (en) * 2007-08-27 2019-05-21 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
EP2887955B1 (en) * 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
JP2015536347A (ja) * 2012-11-16 2015-12-21 ザ ヘンリー エム. ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 淋菌性MtrEペプチドおよびワクチン
JP7136790B2 (ja) * 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
JP2021508672A (ja) * 2017-06-16 2021-03-11 ユナイテッド ニューロサイエンスUnited Neuroscience シヌクレイノパチーの治療のためのアルファ−シヌクレインタンパク質のc末端からのペプチド免疫原及びその製剤
EP3692373A1 (en) * 2017-10-02 2020-08-12 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies
TW202333768A (zh) * 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
TW202000907A (zh) * 2018-05-23 2020-01-01 美商葛利史東腫瘤科技公司 共有抗原

Similar Documents

Publication Publication Date Title
JP2023526500A5 (cg-RX-API-DMAC7.html)
JP2023541669A5 (cg-RX-API-DMAC7.html)
JP2023541670A5 (cg-RX-API-DMAC7.html)
JP2023536995A5 (cg-RX-API-DMAC7.html)
TWI355390B (en) Immunogenic peptide carrier conjugates and methods
US9095536B2 (en) Aβ immunogenic peptide carrier conjugates and methods of producing same
JP2023536746A5 (cg-RX-API-DMAC7.html)
TWI252233B (en) Immunogenic peptide composition for the prevention and treatment of Alzheimer's disease
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
CA3178760A1 (en) Multi-epitope vaccine for the treatment of alzheimer's disease
KR20080097188A (ko) 항아밀로이드 면역성성분, 그 제조방법 및 용도
US9163062B2 (en) Albumin-amyloid peptide conjugates and uses thereof
US20030175285A1 (en) Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid
US20230287050A1 (en) Immunogenic Compounds
KR20240147981A (ko) 항-알파시누클레인 치료 백신
US20080175871A1 (en) Eliciting improved immune responses
CN118660717A (zh) 抗α-突触核蛋白的治疗性疫苗
JP2024538615A5 (cg-RX-API-DMAC7.html)
EA048154B1 (ru) Иммуногенные соединения
RU2021103287A (ru) Самособирающийся пептидный каркас
HK1169831A (en) A beta immunogenic peptide carrier conjugates and methods of producing same
HK1171460A (en) Beta immunogenic peptide carrier conjugates and methods of producing the same